-
Comparative Study
[Differences in the survival after an episode of stroke treated with thrombolytic therapy. Study Ebrictus].
- Jose Luis Clua-Espuny, Rosa Ripolles-Vicente, Carlos Lopez-Pablo, Anna Panisello-Tafalla, Jorgina Lucas-Noll, Cristina Calduch-Noll, M Antonia González-Henares, and M Lluisa Queralt-Tomas.
- EAP Tortosa 1-est, Unidad Docente Tortosa, SAP Terres de l'Ebre, Institut Català Salut, Generalitat Catalunya, Tortosa, España. Electronic address: jlclua@telefonica.net.
- Aten Primaria. 2015 Feb 1; 47 (2): 108-16.
ObjectiveTo seek if there is gender survival difference among patients treated with thrombolytic therapy.DesignCohort study.LocationCommunity based register.Participants91 subjects with an episode of stroke collected since April 2006 up to September 2013 and treated with thrombolytic therapy.InterventionsMonitoring of vital status.MeasurementsWe collected baseline characteristics in Framingham, Regicor, CHA2DS2-VASc, Essen, NIHSS, Barthel scales and outcomes according to gender; person-time incidence rate; survival analysis by Kaplan-Meier's curves, bivariate analysis between survivors and deaths, and Cox multivariate.Results91 patients with middle age 68.02±11.9 years. The men have higher cardiovascular basal risk. The average time of follow-up was 2.95±2.33 years. Incidence rate ratio (IR) shown higher risk in men than in women IR=3.2 (CI 95% 1.2-8.0). The dead cases were older (P=.032); with higher cardiovascular basal risk (P=.040) and more risk of stroke recurrence (P=<.001), with cardiovascular pathology before the stroke (P=.005); more stroke severity (P=.002); and a major fall in the score Barthel one year after the episode (P=.016). The percentage of deaths is significantly higher when the patient is referred by complications to other centres (P=.006) in relation to those referred to home, but just the gender (HR: 1,12; IC 95%: 1,05-1,20) and secondary cardiovascular prevention (HR: 0,13; IC 95%: 0,06-0,28) were associated with higher risk of mortality.ConclusionsAfter stroke episode treated with thrombolytic therapy, men have 12% higher risk of dying than women and don't be treated with secondary cardiovascular prevention rise 7.7 times the mortality risk.Copyright © 2013 Elsevier España, S.L.U. All rights reserved.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.